Description
Some of the main uses of Acebrophylline capsules include:
- Bronchial Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Bronchitis
- Other Respiratory Conditions
Sh3,000.00
Acebrophylline is a medication used primarily in the management of respiratory conditions, particularly those related to airway inflammation and obstruction.
Some of the main uses of Acebrophylline capsules include:
Settings | BROZEN SYS remove | Aciclovir Skin Cream remove | Ampiclox Syrup remove | AMBROSAN SYRUP AMBROXOL 100ML remove | ACTINAC PLUS TABS remove | Artequick Tablets remove |
---|---|---|---|---|---|---|
Image | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
SKU | ||||||
Rating | ||||||
Price | Sh3,000.00 | Sh2,000.00 | Sh2,500.00 | Sh3,000.00 | Sh4,000.00 | Sh11,000.00 |
Stock | ||||||
Availability | ||||||
Add to cart | ||||||
Description | Acebrophylline is a medication used primarily in the management of respiratory conditions, particularly those related to airway inflammation and obstruction. |
| ||||
Content | Some of the main uses of Acebrophylline capsules include:
| Aciclovir belongs to a class of medication known as antivirals. It works by stopping the growth of the virus. This medication does not cure herpes, and it does not prevent passing the infection to someone else. It does not prevent a future occurrence. | It is a powder containing Ampicillin trihydrate B.P. and Cloxacillin. When dispensed as directed each 5 ml of the suspension contains the equivalent of 125 mg Ampicillin and 125 mg Cloxacillin. It is used to treat Infections caused by susceptible organisms where a mixed infection is present and includes penicillin-resistant staphylococci. | Prescribed for various respiratory diseases such as
| It is used to reduce pain and inflammation in conditions like:
| Artequick Tablet Is Used For The Treatment, Control, Prevention, & Improvement Of Malaria And; Acute Liver Injury |
Weight | ||||||
Dimensions | N/A | N/A | N/A | N/A | N/A | N/A |
Additional information |
Reviews
There are no reviews yet.